Most adults lose approximately 15% of their body weight on Wegovy (semaglutide 2.4 mg) over 68 weeks. In the STEP 1 clinical trial, the average participant lost 14.9% of their starting body weight, which amounted to roughly 33.7 pounds. About one in three participants lost 20% or more.

Wegovy Weight Loss Results from Clinical Trials

Wegovy is the brand name for semaglutide 2.4 mg, the highest available dose of this GLP-1 receptor agonist, FDA-approved specifically for chronic weight management. It is the same molecule as Ozempic but formulated and dosed specifically for weight loss rather than diabetes. The STEP clinical trial program provides comprehensive weight loss data.

STEP 1: Primary Weight Loss Data

STEP 1 was the pivotal trial that led to Wegovy's FDA approval. It enrolled 1,961 adults with a BMI of 30 or higher (or 27+ with a weight-related condition) and no diabetes. Key findings at 68 weeks:

• Average weight loss: 14.9% of body weight (vs. 2.4% with placebo)
• Average pounds lost: approximately 33.7 pounds
• 86.4% of participants lost at least 5% of body weight
• 69.1% lost at least 10%
• 50.5% lost at least 15%
• 32.0% lost 20% or more

Results Across the STEP Program

• STEP 2 (adults with type 2 diabetes): Average weight loss of 9.6% at 68 weeks. The diabetes population consistently loses less, likely due to metabolic factors including insulin resistance.
• STEP 3 (with intensive behavioral therapy): Average weight loss of 16.0%, demonstrating that structured lifestyle intervention boosts results beyond medication alone.
• STEP 5 (2-year extension): Average weight loss of 15.2% at 104 weeks, confirming that results are sustained with continued use over two years.
• STEP 8 (vs. liraglutide/Saxenda): Wegovy produced 15.8% weight loss vs. 6.4% for liraglutide, showing substantially greater efficacy than the older GLP-1 weight loss medication.

The SELECT Cardiovascular Trial

The SELECT trial studied Wegovy in 17,604 adults with obesity and established cardiovascular disease but without diabetes. Beyond confirming weight loss of approximately 9.4% (in a population with higher comorbidity burden), the trial demonstrated a 20% reduction in major adverse cardiovascular events. This finding expanded the recognized benefits of Wegovy beyond weight loss alone.

What to Expect in Pounds

Based on the 15% average weight loss from STEP 1:

• Starting at 180 pounds: approximately 27 pounds lost
• Starting at 220 pounds: approximately 33 pounds lost
• Starting at 260 pounds: approximately 39 pounds lost
• Starting at 300 pounds: approximately 45 pounds lost

Weight Loss Timeline

Wegovy uses a 16-week dose escalation schedule before reaching the full 2.4 mg maintenance dose:

• Month 1 (0.25 mg): Introductory dose. Weight loss is minimal, typically 2-4 pounds. Appetite reduction begins.
• Months 2-4 (0.5 mg, 1.0 mg, 1.7 mg): Weight loss accelerates with each dose increase. Most people have lost 4-8% of body weight by the end of month 4.
• Months 5-12 (2.4 mg maintenance): The steepest weight loss period. Monthly loss averages 2-4 pounds.
• Months 12-18: Weight loss gradually slows and plateaus. Most of the total benefit is achieved by this point.

What Influences Individual Results

• Lifestyle changes: Every STEP trial participant received counseling on reduced-calorie diet and physical activity. Patients who actively follow dietary guidance tend to lose more.
• Diabetes status: Type 2 diabetes reduces expected weight loss by roughly 5 percentage points.
• Dose tolerance: A small percentage of patients cannot reach the full 2.4 mg dose due to GI side effects and stay on a lower dose, which produces less weight loss.
• Starting BMI: Higher starting weights yield more pounds lost, though percentage loss is relatively consistent across BMI categories.
• Biological variability: About 14% of STEP 1 participants did not achieve the 5% weight loss threshold, highlighting that individual response varies.

What to Consider

Wegovy is a long-term medication. The STEP 4 trial showed that participants who stopped semaglutide after reaching their weight loss goal regained approximately two-thirds of lost weight within a year. Planning for sustained treatment is important for maintaining results.

Weight loss is not purely linear. Plateaus lasting several weeks are normal and do not mean the medication has stopped working. Tracking trends over months rather than individual weigh-ins gives a more accurate picture of progress.

Your physician should monitor not just weight but also blood pressure, metabolic markers, and overall health improvements. Many patients see benefits in blood pressure, cholesterol, joint pain, and energy levels well before reaching their target weight.

Related Questions

How much weight can you lose on Wegovy in 3 months?

In the first 3 months, most patients lose approximately 5-8% of their starting body weight. For someone weighing 230 pounds, that translates to roughly 12-18 pounds. The first 3 months include the dose titration phase, so the full weight loss effect has not yet been reached.

Is Wegovy more effective than other weight loss drugs?

Wegovy produces significantly more weight loss than older anti-obesity medications like orlistat (5-7%) and liraglutide/Saxenda (6-8%). It produces slightly less weight loss than tirzepatide (Zepbound), which achieved 20-22.5% in clinical trials. Among single-agonist GLP-1 medications, Wegovy remains the most effective option.

Will I keep the weight off after stopping Wegovy?

Most patients regain a substantial portion of lost weight within 1-2 years of discontinuing Wegovy. The STEP 4 trial documented this clearly. This is consistent with how the body responds to weight loss from any intervention, as biological mechanisms work to restore previous weight. Continued use or a structured maintenance plan is recommended.

Does Wegovy work for people with a BMI over 40?

Yes. Clinical trials included participants with BMIs above 40, and these individuals experienced meaningful percentage-based weight loss consistent with the overall trial results. Because their starting weight is higher, the absolute number of pounds lost tends to be greater. Wegovy is approved for adults with a BMI of 30 or higher regardless of the upper range.

Start Your Wegovy Journey with FormBlends

FormBlends connects you with licensed physicians who specialize in GLP-1 therapy for weight management. Your treatment plan includes a complete medical evaluation, guided dose titration, and ongoing clinical support to help you achieve and maintain your results. Start your consultation today.